Skip to content

Study Details

Tezepelumab: A Study Drug for Patients with Eosinophilic Esophagitis (EoE)

(IRB#: IRB_00162145)

Eosinophilic Esophagitis (EoE) is a disease that may cause vomiting and heartburn and make swallowing difficult. Tezepelumab is a study drug for patients with EoE. Research is needed to learn if Tezepelumab is safe and effective at helping people with EoE. We also hope to better understand EoE and health problems related to the disease. The information we gain may aid future patients.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18 to 80 years old
  • Diagnosis of EoE with 2 issues a week 4 weeks before the first visit
  • Stable diet for at least 8 weeks before the first visit
  • Participants of childbearing age must use specific birth control
  • Attend in person at the University of Utah

Exclusion Criteria

  • Other disorders related to EoE
  • Using a feeding tube
  • History of Cancer
  • Active serious infection or receiving medications or infection 7 days before the first visit
  • Pregnant

Will I be paid for my time?


For more information contact:

Amy Holman


IRB#: IRB_00162145

PI: Kathryn Peterson


Approval Date: 2023-05-10 06:00:00

Specialties: Gastroenterology

Last Updated: 6/8/23